Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

InMed Pharmaceuticals (INM) Return on Capital Employed: 2023-2025

Historic Return on Capital Employed for InMed Pharmaceuticals (INM) over the last 3 years, with Jun 2025 value amounting to 0.67%.

  • InMed Pharmaceuticals' Return on Capital Employed rose 13.00% to 0.62% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.62%, marking a year-over-year increase of 13.00%. This contributed to the annual value of 0.67% for FY2025, which is 8.00% up from last year.
  • Latest data reveals that InMed Pharmaceuticals reported Return on Capital Employed of 0.67% as of FY2025, which was up 10.15% from 0.75% recorded in FY2024.
  • InMed Pharmaceuticals' 5-year Return on Capital Employed high stood at 0.67% for FY2025, and its period low was 0.75% during FY2024.
  • Over the past 3 years, InMed Pharmaceuticals' median Return on Capital Employed value was 0.74% (recorded in 2023), while the average stood at 0.72%.
  • Per our database at Business Quant, InMed Pharmaceuticals' Return on Capital Employed fell by 1bps in 2024 and then increased by 8bps in 2025.
  • Over the past 3 years, InMed Pharmaceuticals' Return on Capital Employed (MRY) stood at 0.74% in 2023, then decreased by 1bps to 0.75% in 2024, then increased by 10bps to 0.67% in 2025.
  • Its Return on Capital Employed stands at 0.67% for FY2025, versus 0.75% for FY2024 and 0.74% for FY2023.